Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized international GHSG HD18 trial
Background - Persisting cancer-related fatigue impairs health-related quality of life (HRQoL) and social reintegration in patients with Hodgkin’s lymphoma (HL). The GHSG HD18 trial established treatment de-escalation for advanced-stage HL guided by positron emission tomography after two cycles (PET-...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 2024
|
| In: |
Annals of oncology
Year: 2024, Jahrgang: 35, Heft: 3, Pages: 276-284 |
| ISSN: | 1569-8041 |
| DOI: | 10.1016/j.annonc.2023.11.014 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.annonc.2023.11.014 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0923753423051025 
|
| Verfasserangaben: | J. Ferdinandus, H. Müller, C. Damaschin, A.S. Jacob, J. Meissner, F. Krasniqi, U. Mey, D. Schöndube, J. Thiemer, S. Mathas, J. Zijlstra, R. Greil, M. Feuring-Buske, J. Markova, J.U. Rüffer, C. Kobe, H.-T. Eich, C. Baues, M. Fuchs, P. Borchmann & K. Behringer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1905210531 | ||
| 003 | DE-627 | ||
| 005 | 20241205180114.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241009s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2023.11.014 |2 doi | |
| 035 | |a (DE-627)1905210531 | ||
| 035 | |a (DE-599)KXP1905210531 | ||
| 035 | |a (OCoLC)1475314683 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Ferdinandus, Justin |e VerfasserIn |0 (DE-588)119441494X |0 (DE-627)1676381481 |4 aut | |
| 245 | 1 | 0 | |a Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma |b results from the randomized international GHSG HD18 trial |c J. Ferdinandus, H. Müller, C. Damaschin, A.S. Jacob, J. Meissner, F. Krasniqi, U. Mey, D. Schöndube, J. Thiemer, S. Mathas, J. Zijlstra, R. Greil, M. Feuring-Buske, J. Markova, J.U. Rüffer, C. Kobe, H.-T. Eich, C. Baues, M. Fuchs, P. Borchmann & K. Behringer |
| 264 | 1 | |c March 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar 5 December 2023, Version des Artikels 21 February 2024 | ||
| 500 | |a Note: This study was previously presented at ICML 2023 meeting in Lugano, CH | ||
| 500 | |a Gesehen am 09.10.2024 | ||
| 520 | |a Background - Persisting cancer-related fatigue impairs health-related quality of life (HRQoL) and social reintegration in patients with Hodgkin’s lymphoma (HL). The GHSG HD18 trial established treatment de-escalation for advanced-stage HL guided by positron emission tomography after two cycles (PET-2) as new standard. Here, we investigate the impact of treatment de-escalation on long-term HRQoL, time to recovery from fatigue (TTR-F), and time to return to work (TTR-W). - Patients and methods - Patients received European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and life situation questionnaires at baseline, interim, end of treatment, and yearly follow-up. TTR-F was defined as time from the end of chemotherapy until the first fatigue score <30. TTR-W was analyzed in previously working or studying patients and measured from the end of treatment until the first documented work or education. We compared duration of treatment on TTR-F and TTR-W using Cox proportional hazards regression adjusted for confounding variables. - Results - HRQoL questionnaires at baseline were available in 1632 (83.9%) of all randomized patients. Overall, higher baseline fatigue and age were significantly associated with longer TTR-F and TTR-W and male sex with shorter TTR-W. Treatment reduction from eight to four chemotherapy cycles led to a significantly shorter TTR-F [hazard ratio (HR) 1.41, P = 0.008] and descriptively shorter TTR-W (HR 1.24, P = 0.084) in PET-2-negative patients. Reduction from six to four cycles led to non-significant but plausible intermediate accelerations. The addition of rituximab caused significantly slower TTR-F (HR 0.70, P = 0.0163) and TTR-W (HR 0.64, P = 0.0017) in PET-2-positive patients. HRQoL at baseline and age were the main determinants of 2-year HRQoL. - Conclusions - Individualized first-line treatment in patients with advanced-stage HL considerably shortens TTR-F and TTR-W in PET-2-negative patients. Our results support the use of response-adapted shortened treatment duration for patients with HL. | ||
| 650 | 4 | |a fatigue | |
| 650 | 4 | |a Hodgkin’s lymphoma | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a recovery | |
| 650 | 4 | |a return to work | |
| 650 | 4 | |a survivorship | |
| 700 | 1 | |a Müller, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Damaschin, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jacob, A. S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meißner, Julia |e VerfasserIn |0 (DE-588)1236765966 |0 (DE-627)176254850X |4 aut | |
| 700 | 1 | |a Krasniqi, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mey, U. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schöndube, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thiemer, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mathas, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zijlstra, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Greil, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Feuring-Buske, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Markova, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rüffer, J. U. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kobe, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eich, H. -T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Baues, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fuchs, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Borchmann, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Behringer, K. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 35(2024), 3 vom: März, Seite 276-284 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma results from the randomized international GHSG HD18 trial |
| 773 | 1 | 8 | |g volume:35 |g year:2024 |g number:3 |g month:03 |g pages:276-284 |g extent:9 |a Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma results from the randomized international GHSG HD18 trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.annonc.2023.11.014 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0923753423051025 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241009 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1236765966 |a Meißner, Julia |m 1236765966:Meißner, Julia |d 910000 |d 910100 |e 910000PM1236765966 |e 910100PM1236765966 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 999 | |a KXP-PPN1905210531 |e 4589537346 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"March 2024"}],"language":["eng"],"relHost":[{"corporate":[{"roleDisplay":"Herausgebendes Organ","role":"isb","display":"European Society for Medical Oncology"}],"pubHistory":["1.1990 -"],"recId":"320428796","disp":"Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma results from the randomized international GHSG HD18 trialAnnals of oncology","note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"id":{"zdb":["2003498-2"],"eki":["320428796"],"issn":["1569-8041"]},"title":[{"subtitle":"official journal of the European Society for Medical Oncology","title_sort":"Annals of oncology","title":"Annals of oncology"}],"part":{"extent":"9","year":"2024","pages":"276-284","text":"35(2024), 3 vom: März, Seite 276-284","volume":"35","issue":"3"},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedDisp":"1990-","dateIssuedKey":"1990","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford"}]}],"person":[{"family":"Ferdinandus","roleDisplay":"VerfasserIn","role":"aut","display":"Ferdinandus, Justin","given":"Justin"},{"roleDisplay":"VerfasserIn","family":"Müller","given":"H.","display":"Müller, H.","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Damaschin","display":"Damaschin, C.","role":"aut","given":"C."},{"given":"A. S.","display":"Jacob, A. S.","role":"aut","roleDisplay":"VerfasserIn","family":"Jacob"},{"role":"aut","display":"Meißner, Julia","given":"Julia","family":"Meißner","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Krasniqi","given":"F.","role":"aut","display":"Krasniqi, F."},{"role":"aut","display":"Mey, U.","given":"U.","roleDisplay":"VerfasserIn","family":"Mey"},{"given":"D.","display":"Schöndube, D.","role":"aut","roleDisplay":"VerfasserIn","family":"Schöndube"},{"given":"J.","role":"aut","display":"Thiemer, J.","family":"Thiemer","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Mathas, S.","given":"S.","roleDisplay":"VerfasserIn","family":"Mathas"},{"family":"Zijlstra","roleDisplay":"VerfasserIn","display":"Zijlstra, J.","role":"aut","given":"J."},{"given":"R.","role":"aut","display":"Greil, R.","family":"Greil","roleDisplay":"VerfasserIn"},{"given":"M.","role":"aut","display":"Feuring-Buske, M.","family":"Feuring-Buske","roleDisplay":"VerfasserIn"},{"given":"J.","role":"aut","display":"Markova, J.","roleDisplay":"VerfasserIn","family":"Markova"},{"display":"Rüffer, J. U.","role":"aut","given":"J. U.","family":"Rüffer","roleDisplay":"VerfasserIn"},{"given":"C.","display":"Kobe, C.","role":"aut","roleDisplay":"VerfasserIn","family":"Kobe"},{"role":"aut","display":"Eich, H. -T.","given":"H. -T.","roleDisplay":"VerfasserIn","family":"Eich"},{"roleDisplay":"VerfasserIn","family":"Baues","given":"C.","role":"aut","display":"Baues, C."},{"display":"Fuchs, M.","role":"aut","given":"M.","roleDisplay":"VerfasserIn","family":"Fuchs"},{"family":"Borchmann","roleDisplay":"VerfasserIn","given":"P.","role":"aut","display":"Borchmann, P."},{"roleDisplay":"VerfasserIn","family":"Behringer","given":"K.","display":"Behringer, K.","role":"aut"}],"name":{"displayForm":["J. Ferdinandus, H. Müller, C. Damaschin, A.S. Jacob, J. Meissner, F. Krasniqi, U. Mey, D. Schöndube, J. Thiemer, S. Mathas, J. Zijlstra, R. Greil, M. Feuring-Buske, J. Markova, J.U. Rüffer, C. Kobe, H.-T. Eich, C. Baues, M. Fuchs, P. Borchmann & K. Behringer"]},"physDesc":[{"extent":"9 S.","noteIll":"Illustrationen"}],"note":["Online verfügbar 5 December 2023, Version des Artikels 21 February 2024","Note: This study was previously presented at ICML 2023 meeting in Lugano, CH","Gesehen am 09.10.2024"],"recId":"1905210531","id":{"eki":["1905210531"],"doi":["10.1016/j.annonc.2023.11.014"]},"title":[{"title":"Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma","title_sort":"Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma","subtitle":"results from the randomized international GHSG HD18 trial"}]} | ||
| SRT | |a FERDINANDUIMPACTOFIN2024 | ||